Galena Biopharma Presents GALE-401 (Anagrelide Controlled Release) Phase 2 Data at the European Hematology Association 20th Congress
15 juin 2015 07h05 HE
|
Galena Biopharma, Inc.
GALE-401 was well tolerated with primarily Grade 1 and 2 toxicities
Phase 2 pilot study demonstrated an Overall Response Rate of 78%
PORTLAND, Ore., June 15, 2015 (GLOBE NEWSWIRE) --...
Galena Biopharma to Present at the Sachs Immuno-Oncology BD&L and Investment Forum
28 mai 2015 16h10 HE
|
Galena Biopharma, Inc.
PORTLAND, Ore., May 28, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that...
Galena Biopharma Announces Publication of Two Abstracts at the 2015 American Society of Clinical Oncology Annual Meeting
27 mai 2015 07h05 HE
|
Galena Biopharma, Inc.
GALE-301 demonstrates promising preliminary efficacy data with a projected 78% reduction in relative risk of recurrence in the 1000 mcg dose cohort
Leica Biosystem's Bond Oracle HER2...
Galena Biopharma to Present GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial Data at the European Hematology Association 20th Congress
22 mai 2015 07h05 HE
|
Galena Biopharma, Inc.
PORTLAND, Ore., May 22, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that...
Galena Biopharma Reports First Quarter 2015 Financial Results
07 mai 2015 16h15 HE
|
Galena Biopharma, Inc.
Completed enrollment in the NeuVax Phase 3 PRESENT breast cancer immunotherapy clinical trial
Commercial programs continue on track
Abstral® (fentanyl) Sublingual...
Galena Biopharma to Report First Quarter Financial Results on Thursday, May 7, 2015
23 avr. 2015 07h05 HE
|
Galena Biopharma, Inc.
PORTLAND, Ore., April 23, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address...
Galena Biopharma Completes Over-Enrollment of NeuVax(TM) (nelipepimut-S) Phase 3 PRESENT Clinical Trial
14 avr. 2015 07h21 HE
|
Galena Biopharma, Inc.
PORTLAND, Ore., April 14, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that...
Galena Biopharma Announces Closing of Over-Allotment Option, Increasing Total Gross Proceeds to $43.7 Million
10 avr. 2015 11h15 HE
|
Galena Biopharma, Inc.
PORTLAND, Ore., April 10, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that...
Galena Biopharma to Present at the 14th Annual Needham Healthcare Conference
31 mars 2015 07h05 HE
|
Galena Biopharma, Inc.
PORTLAND, Ore., March 31, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that...
Galena Biopharma Expands Patient Population in NeuVax(TM) (nelipepimut-S) and trastuzumab Phase 2b Combination Clinical Trial in HER2 1+/2+ Patients
26 mars 2015 07h05 HE
|
Galena Biopharma, Inc.
PORTLAND, Ore., March 26, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that...